Dubai, UAE,December 21, 2025
LAVO Protocol, a pioneering Decentralized Science (DeSci) ecosystem bridging blockchain technology with industrial-grade biotechnology, today announced the signing of a strategic Memorandum of Understanding (MOU) with Almak Group, a prominent international investment conglomerate headquartered in Dubai.
This landmark partnership marks a significant milestone in the convergence of sovereign-level capital and Web3 innovation.
The collaboration aims to accelerate the development of LAVO’s longevity research infrastructure and expand its “Bio-Bridging” ecosystem into key Asian and Middle Eastern markets.
A Union of Royal Vision and Biotech Innovation
The MOU outlines a comprehensive framework for cooperation where Almak Group will provide strategic backing to LAVO Protocol. This support encompasses capital investment, global network integration, and resources to facilitate LAVO’s entry into the rapidly growing biotechnology sectors of UAE region.
Almak Group is a diversified investment powerhouse led by Sheikh Ali Rashed Ali Saeed Al Maktoum, a member of Dubai’s ruling family and a relative of His Highness Sheikh Mohammed bin Rashid Al Maktoum. Sheikh Ali has established himself as a forward-thinking leader dedicated to fostering economic bridges between Dubai and the global market. Under his guidance, Almak Group has built an extensive portfolio spanning renewable energy, artificial intelligence, real estate, and financial services.”We are constantly seeking technologies that have the power to reshape industries,” said by representative from Almak Group. “LAVO Protocol’s unique approach to tokenizing real-world biological assets and democratizing longevity research aligns perfectly with our vision for the future of technology and healthcare.”
LAVO Protocol: Infrastructure Powering the Next Era of Biotech
LAVO Protocol is the world’s first ecosystem designed to connect decentralized liquidity directly with established, revenue-generating biotechnology. Unlike speculative crypto projects, LAVO is the execution layer for longevity science.
DeSci Infrastructure: A decentralized network that allows users to own their health data and participate in the governance of scientific research.
LAVO Labs: The ecosystem’s biotech engine, powered by strategic partner Innova Laboratory Technologies, creates a direct pathway from research to retail. This ensures that the platform is backed by tangible assets, including exclusive proprietary ExoBiome technology and GMP-compliant manufacturing capabilities
Expert Leadership: The project is led by Dr. Jac, an expert in regenerative medicine and stem cell research, and Dr. Anton Philip Battiade Giacomo, a globally respected specialist in exosome technologies with over 20 years of experience.
By integrating Almak Group’s financial prowess with LAVO’s technical infrastructure, the partnership is poised to solve the “Valley of Death” in pharmaceutical research, ensuring that breakthrough longevity treatments reach the market faster and more efficiently.
About LAVO Protocol
LAVO Protocol is a foundational biotechnology platform operating at the intersection of Web3 and longevity science. Registered in the United States, LAVO leverages blockchain to transform biomedical research into transparent, on-chain assets. Through its first flagship token $EXO and its “Bio-Bridging” model, LAVO empowers communities to fund and benefit from the future of life sciences.
Disclaimer
This press release is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to sell any securities. The collaboration mentioned herein represents a strategic intent and is subject to the terms of definitive agreements. Cryptocurrencies and digital assets are subject to market risks and regulatory uncertainty. Professional due diligence is recommended when engaging with any high-growth technology ventures.
Website: https://lavoprotocol.io/